Along these lines, the SREBP antagonist, agonist of PPARα, GLP-1RA, SGLT-2 blockers and ongoing clinical trials focusing on dietary intervention hold promise for the treatment of obesity mediated nephropathy. Here, SLC5A2 is linked to obesity due to melanocortin 4 receptor deficiency.